Option chain shows key data for Alterity Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alterity Therapeutics.

Alterity Therapeutics (NASDAQ:ATHE) Stock, Option Chain

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Nasdaq index

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CRGX

NTCT

TECX

Nasdaq Moves Lower; Meta Platforms Posts Strong Sales

Medicine,Development,Laboratory:,Caucasian,Female,Scientist,Using,Microscope,,Analyzes,Petri

Movers

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

What&#39;s Going On With Alterity Therapeutics Shares Thursday?

Wall Street_Dow

AMOD

CLEU

SLXN

TSLA

Dow Jumps Over 100 Points; Tesla Earnings Miss Views

Alterity Therapeutics Ltd

ATHENS INTL ARPT S A by ATHENS INTL ARPT SA

ATHENS INTL ARPT SA U/ADR by ATHENS INTL ARPT SA

ATHENA BITCOIN GLOBAL by ATHENA BITCOIN GLOBAL

Athena Bitcoin Global

ATHENA GOLD CORPORATION by Athena Gold Corporation

Athena Gold Corp

ATHENA TECH ACQ CP II A by Athena Technology Acquisition Corp. II

Athena Technology Acquisition Corp II

Athena Technology Acquisition Corp II Units (1 Ord Share Class A & 1/2 War)

Athena Technology Acquisition Corp II Warrants (01/01/9999)

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 7.750% Fixed-Rate Reset Perpetual Non-Cumulative Preference Share, Series E

Athene Holding Ltd

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 4.875% Fixed-Rate Perpetual Non-Cumulative Preference Share, Series D

Athene Holding Ltd. Depositary Shares, each representing a 1/1,000th Interest in a Share of 6.375% Fixed-Rate Reset Perpetual Non-Cumulative Preference Shares, Series C

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Share, Series A

Athene Holding Ltd. Depositary Shares, Each Representing a 1/1,000th Interest in a 5.625% Fixed Rate Perpetual Non- Cumulative Preference Share, Series B, par value $1.00 per share

Athene Holding Ltd. 7.250% Fixed-Rate Reset Junior Subordinated Debentures due 2064

Athenex Inc

ATHENS WTR&SWGE PUB EYDAP by Athens Water & Sewage Public Co. Eydap

Athens Water Supply & Sewerage Co

Athersys Inc

Press Releases

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Health Care

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Peraso Inc. (NASDAQ: PRSO): The Only Pure-Play mmWave Stock Poised for Growth – More Stocks Inside

Alterity Therapeutics Raises A$40.0 million in Placement

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

BNZI

KZIA

PNPNF

PRSO

TSXV:PNPN

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Alterity Therapeutics

Avalo Therapeutics

BeyondSpring

Cabaletta Bio

Cibus

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Citius Oncology

Cue Biopharma

Gain Therapeutics

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Kronos Bio

MAIA Biotechnology

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Quince Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

Comments

Alterity Therapeutics

Alterity Therapeutics (ATHE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga